AGENUS INC (AGEN:NASDAQ)
$7.66 -0.15 (-1.9206%)
Analysed AGENUS INC (AGEN:NASDAQ) News Sources
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
13-07-2026
marketbeat.com
Agenus shares surge as company secures up to $340M to advance colon cancer trial
13-07-2026
proactiveinvestors.com
AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment
13-07-2026
stocktwits.com
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?
14-07-2026
yahoo.com
Agenus stock doubles as biotech narrows Phase 3 bet
14-07-2026
thestreet.com
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing
17-07-2026
yahoo.com
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
07-08-2026
yahoo.com
Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions
16-08-2026
yahoo.com
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
26-08-2026
yahoo.com
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
28-08-2026
yahoo.com
What is the current price of AGENUS INC (AGEN:NASDAQ)?
The current price of AGENUS INC (AGEN:NASDAQ) is $7.66.
AGENUS INC (AGEN:NASDAQ) absolute price change since previous trading day?
The absolute price change of AGENUS INC (AGEN:NASDAQ) since the previous trading day is $-0.15.
AGENUS INC (AGEN:NASDAQ) percentage price change since previous trading day?
The percentage price change of AGENUS INC (AGEN:NASDAQ) since the previous trading day is -1.9206%.
What is the most recent average sentiment score for AGENUS INC (AGEN:NASDAQ)?
The most recent average sentiment score for AGENUS INC (AGEN:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for AGENUS INC (AGEN:NASDAQ)?
The most recent sentiment for AGENUS INC (AGEN:NASDAQ) is .
SEC-8K** Filing Available For AGENUS INC (AGEN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.